Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $75.00 Price Target at The Goldman Sachs Group

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price raised by The Goldman Sachs Group from $60.00 to $75.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

KNSA has been the topic of several other reports. Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Citigroup raised their price target on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Finally, Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $68.00.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $63.05 on Thursday. The firm’s fifty day moving average is $56.75 and its two-hundred day moving average is $49.88. The firm has a market cap of $4.85 billion, a PE ratio of 70.06 and a beta of 0.07. Kiniksa Pharmaceuticals International has a twelve month low of $26.27 and a twelve month high of $67.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period last year, the firm posted $0.11 earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Equities analysts forecast that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 13,099 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the transaction, the chief executive officer owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 628,427 shares of company stock valued at $32,833,228. 51.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently made changes to their positions in KNSA. Mark Sheptoff Financial Planning LLC lifted its holdings in Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after purchasing an additional 250 shares during the last quarter. Mariner LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 2.0% in the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after purchasing an additional 266 shares during the last quarter. First Trust Advisors LP raised its position in shares of Kiniksa Pharmaceuticals International by 3.1% in the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after purchasing an additional 293 shares during the period. Virtus Investment Advisers LLC raised its position in shares of Kiniksa Pharmaceuticals International by 2.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after purchasing an additional 406 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after buying an additional 508 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.